Becton Dickinson and Co

Becton Dickinson and Co(BDX)の株式分析

$191.750

-1.994 (-1.04%)終値時点

Loading chart…
高値
195.990
始値
194.420
出来高加重平均価格
192.65
出来高
1.41M
時価総額
66.74B
安値
190.210
売買代金
272.15M
EV/EBITDA(TTM)
12.68

Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. It operates through five segments: BD Medical Essentials, BD Connected Care, BD BioPharma Systems, BD Interventional, and BD Life Sciences. BD Medical Essentials segment includes medication delivery solutions and specimen management. BD Connected Care segment includes medication management solutions and advanced patient monitoring. BD Interventional segment includes urology and critical care, peripheral intervention and surgery. Its Life Sciences segment includes diagnostic solutions and biosciences.

www.bd.com

AI分析 of Becton Dickinson and Co (BDX)

買い

Becton Dickinson (BDX) is a good buy right now due to its current price of $191.75, which is below the average analyst price target of $200, suggesting potential upside. The stock has a strong gross margin of 46.76% and a forward P/E ratio of 13.72, indicating solid profitability and reasonable valuation. However, the main risk is the recent dip in net income, with a reported loss of $31 million in Q2 2026, which could impact future performance.

アナリスト評価(15)

上値余地 +0.46%
買い
10 買い
5 中立
0 売り
現在: 191.75
安値
157.00
平均
192.64
高値
232.00

Barclays

2026-10-07

目標株価

$165

アンダーウェイト

BofA

2026-08-31

目標株価

$200

中立

RBC Capital

2026-08-13

目標株価

$190

Sector Perform

Citi

2026-08-13

目標株価

$208

買い

RBC Capital

2026-08-07

目標株価

$180

Sector Perform

バリュエーション指標

Becton Dickinson and Co(BDX)の現在の予想PERは13.72で、5年平均は17.19です。

予想PER

適正
5年平均 P/E
17.19
現在のP/E
13.72
割高
20.85
割安
13.52

予想EV/EBITDA

適正
5年平均 EV/EBITDA
14.11
現在のEV/EBITDA
12.68
割高
16.40
割安
11.82

予想PSR

適正
5年平均 P/S
3.18
現在のP/S
2.67
割高
3.76
割安
2.59

Alphio AI による BDX の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%BDX

$193.53

シナリオ価格

基

基本

基本 · 50%BDX

$172.62

シナリオ価格

弱

弱気

弱気 · 25%BDX

$171.68

シナリオ価格

BDX を保有するクジラ

J

John W. Bristol & Co., Inc.

+ を保有BDX

+6.49%

3か月リターン

V

Veritas Asset Management LLP

+ を保有BDX

+5.30%

3か月リターン

J

James Hambro & Partners LLP

+ を保有BDX

+4.65%

3か月リターン

B

Beutel Goodman & Company Ltd.

+ を保有BDX

+4.35%

3か月リターン

F

Fort Washington Investment Advisors, Inc.

+ を保有BDX

+4.29%

3か月リターン

G

Guyasuta Investment Advisors, Incorporated

+ を保有BDX

+3.73%

3か月リターン

イベントタイムライン

2026-10-07 (ET)

08:30:00

BD Reports Positive Nine-Month Results for Revello Vascular Covered Stent

2026-10-06 (ET)

07:00:00

Becton Dickinson Partners with U.S. Government for $19B Manufacturing Expansion

2026-09-21 (ET)

17:00:00

Becton, Dickinson Appoints Arthur Hu as Chief Information Officer

2026-08-12 (ET)

07:00:00

Becton Dickinson Completes Enrollment in PREVENT Clinical Trial

ニュース

BDX のよくある質問 — Alphio AI が回答

Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. It operates through five segments: BD Medical Essentials, BD Connected Care, BD BioPharma Systems, BD Interventional, and BD Life Sciences. BD Medical Essentials segment includes medication delivery solutions and specimen management. BD Connected Care segment includes medication management solutions and advanced patient monitoring. BD Interventional segment includes urology and critical care, peripheral intervention and surgery. Its Life Sciences segment includes diagnostic solutions and biosciences. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Becton Dickinson (BDX) is a good buy right now due to its current price of $191.75, which is below the average analyst price target of $200, suggesting potential upside. The stock has a strong gross margin of 46.76% and a forward P/E ratio of 13.72, indicating solid profitability and reasonable valuation. However, the main risk is the recent dip in net income, with a reported loss of $31 million in Q2 2026, which could impact future performance.

15 analysts cover BDX: 10 rate it Buy, 5 Hold and 0 Sell. The average price target is 192.64.

コミュニティ

もっと見る ↗
range_bonder2026/9/16

Beldex @BeldexCoin recently published two research pieces, and I think they are interesting to look at together. One is about age verification: you only need to prove you are over 18, without handing over your birthday, identity, and nationality all at once. At the same time, it checks that the credential signature is real, that the age is actually derived from that birthday, that the same number is locked in the commitment, and that this number is not below 18. In the end, the other party only gets one result: you meet the age requirement. This is still research for now. Beldex Research Labs is next trying Bulletproof to make the proof smaller and push verification cost down further. It has not yet become a ready feature in BChat or the wallet. The other is VRF consensus. Beldex's current PoS already has a layer of random validator selection. What VRF aims to add is verifiable randomness: everyone can later verify whether the result of who got selected followed the rules, while before the draw it is harder to predict in advance who the next batch will be. The team currently places the VRF-based PoS hardfork in Q1 2027. This is also a later upgrade, not something already fully switched over on mainnet now. One is dealing with how much identity information should be exposed, and the other is dealing with how randomness in consensus should be proven. These two research lines at Beldex are actually quite consistent in direction: provide enough information, and avoid exposing extra information as much as possible.

もっと見る
登録またはログインして議論に参加

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める